Conestoga Capital Advisors LLC boosted its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 3.4% in the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 980,247 shares of the biotechnology company's stock after purchasing an additional 32,665 shares during the period. Repligen comprises 1.9% of Conestoga Capital Advisors LLC's portfolio, making the stock its 20th largest position. Conestoga Capital Advisors LLC owned 1.75% of Repligen worth $124,727,000 as of its most recent SEC filing.
A number of other hedge funds have also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its position in shares of Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company's stock worth $1,027,165,000 after purchasing an additional 743,815 shares during the last quarter. Vanguard Group Inc. raised its stake in Repligen by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 5,101,090 shares of the biotechnology company's stock valued at $734,251,000 after buying an additional 56,723 shares in the last quarter. Champlain Investment Partners LLC lifted its holdings in Repligen by 8.6% during the 4th quarter. Champlain Investment Partners LLC now owns 1,543,530 shares of the biotechnology company's stock worth $222,176,000 after buying an additional 122,595 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of Repligen by 23.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,010,896 shares of the biotechnology company's stock worth $145,508,000 after acquiring an additional 191,439 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in shares of Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company's stock valued at $132,227,000 after acquiring an additional 594,189 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Analysts Set New Price Targets
RGEN has been the topic of several research analyst reports. Royal Bank Of Canada reduced their price objective on Repligen from $202.00 to $189.00 and set an "outperform" rating on the stock in a research note on Wednesday, April 30th. Wall Street Zen upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research report on Thursday, May 8th. JPMorgan Chase & Co. lowered their price objective on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a research note on Tuesday, April 29th. Finally, HC Wainwright restated a "buy" rating and set a $180.00 price objective on shares of Repligen in a research report on Monday, May 5th. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $173.25.
View Our Latest Stock Report on Repligen
Repligen Price Performance
RGEN traded down $3.47 during trading on Wednesday, reaching $117.54. The stock had a trading volume of 1,449,380 shares, compared to its average volume of 738,146. The stock has a 50 day moving average of $128.74 and a two-hundred day moving average of $142.37. The company has a quick ratio of 5.79, a current ratio of 6.79 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $6.60 billion, a price-to-earnings ratio of -261.20, a price-to-earnings-growth ratio of 3.46 and a beta of 1.10. Repligen Corporation has a 1-year low of $102.97 and a 1-year high of $182.52.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The business had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. During the same quarter in the prior year, the firm posted $0.28 earnings per share. The company's revenue was up 10.4% on a year-over-year basis. As a group, equities analysts anticipate that Repligen Corporation will post 1.72 EPS for the current fiscal year.
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
